Clinical Activity Areas:

• Development of technologies for the production of bioimplants from allo- and xenogenic bone, as well as bioengineered constructs based on bone matrix combined with stromal cells, medicinal substances, platelet-rich plasma or fibrin (PRP or PRF)
• Clinical implementation of developed bone bioimplants of various shapes as osteoplastic material for bone defect replacement; investigation of their interaction with the patient’s body

Clinical Achievements:

We offer dehydrated allogeneic bone materials for clinical use: volumetric bone implants “OMS-A-OKI”®, cortico-cancellous granulate “OMS-A-KGG”® (5–10 mm), and bone powder-chips “OMS-A-KPK”® (0.5–2.0 mm). The implantable biomaterials are packaged and sterilised using radiation (patents No. 119699 UA, 119700 UA, quality management system certificate No. UA8O072.02012214.4-2022).

In addition, allogeneic bone materials may be denatured (decellularised and cleared of most organic components) or demineralised (cleared of inorganic components). Our implantable biomaterials can serve as a matrix for tissue-engineered constructs in combination with medicinal substances, platelet-rich plasma or fibrin (PRP or PRF), and the patient’s stem cells for bone defect replacement and optimisation of the osteoreparative process in patients after bone grafting surgical interventions.